By inhibiting the STAT3/MCL1 signaling axis and predisposing NSCLC cells to ferroptosis, our study provides significant insights for the development of innovative combinations to treat advanced NSCLC patients. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.